Published in J Natl Cancer Inst on March 13, 2014
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders | NCT04398628
Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol (2015) 2.98
Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers. Support Care Cancer (2015) 2.11
The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials. JAMA Oncol (2016) 2.09
Drugs, cancer and end-of-life care: a case study of pharmaceuticalization? Soc Sci Med (2014) 2.03
In and out, good and bad news, of generalizability of SWOG treatment trial results. J Natl Cancer Inst (2014) 0.86
Enhancing cancer registry data for comparative effectiveness research (CER) project: overview and methodology. J Registry Manag (2014) 0.84
Can quality of life assessments differentiate heterogeneous cancer patients? PLoS One (2014) 0.81
Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib? Cancer Res Treat (2015) 0.79
Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials. Cancer Epidemiol Biomarkers Prev (2016) 0.77
Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial. Biol Blood Marrow Transplant (2015) 0.77
A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials. PLoS One (2016) 0.76
Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer J (2017) 0.75
From evidence to clinical practice in blood and marrow transplantation. Blood Rev (2015) 0.75
Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer. Obstet Gynecol (2016) 0.75
A randomized phase II dose-response exercise trial among colon cancer survivors: Purpose, study design, methods, and recruitment results. Contemp Clin Trials (2016) 0.75
Pemetrexed for ovarian cancer: a systematic review of the published literature and a consecutive series of patients treated in a nonclinical trial setting. Case Rep Oncol (2014) 0.75
Comparative effectiveness research in gynecologic oncology. Cancer Treat Res (2015) 0.75
The challenges of symptom management for patients with multimorbidity in research and practice: a thematic review. Prog Palliat Care (2016) 0.75
Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplant Outcomes. Biol Blood Marrow Transplant (2017) 0.75
Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet (1993) 38.49
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care (2002) 21.63
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med (2001) 18.77
Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA (2004) 14.05
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med (2001) 11.73
Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med (1999) 11.44
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol (1999) 9.20
Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer (2008) 6.96
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med (1998) 6.84
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol (2000) 6.06
Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health (1998) 5.55
Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". J Clin Epidemiol (2001) 5.21
Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet (2004) 4.99
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol (2001) 4.73
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol (2010) 4.69
How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol (2002) 4.68
Ethical issues in the design and conduct of randomised controlled trials. Health Technol Assess (1998) 4.55
Results of a breast-cancer-surgery trial compared with observational data from routine practice. Lancet (1996) 3.78
Treatment centre size, entry to trials, and survival in acute lymphoblastic leukaemia. Arch Dis Child (1989) 3.76
Centralised treatment, entry to trials and survival. Br J Cancer (1994) 3.46
The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med (1986) 3.27
Hazard rate estimation under random censoring with varying kernels and bandwidths. Biometrics (1994) 3.12
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol (2009) 2.73
Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. BMJ (1989) 2.46
Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer (2006) 2.30
Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials. Cancer (1985) 2.28
Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research. J Clin Epidemiol (1997) 2.21
Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol (2005) 2.19
Systematic review to determine whether participation in a trial influences outcome. BMJ (2005) 2.19
Survival in childhood acute lymphocytic leukemia: effect of protocol and place of treatment. Cancer Invest (1983) 2.16
Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst (1996) 2.12
Survival from acute non-lymphocytic leukaemia, 1971-88: a population based study. Arch Dis Child (1994) 2.06
The selection of cases for randomised trials: a registry survey of concurrent trial and non-trial patients. The British Stomach Cancer Group. Br J Cancer (1992) 1.94
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol (1998) 1.91
Nephroblastoma: treatment during 1970-3 and the effect on survival of inclusion in the first MRC trial. Br Med J (1979) 1.84
Childhood NHL in Switzerland: incidence and survival of 120 study and 42 non-study patients. Med Pediatr Oncol (1995) 1.77
Selection factors in clinical trials: results from the Community Clinical Oncology Program Physician's Patient Log. Cancer Treat Rep (1987) 1.76
Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol (2010) 1.70
Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst (1995) 1.67
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol (1994) 1.49
Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer (2001) 1.47
Selection bias in clinical trials. J Clin Oncol (1985) 1.42
Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies. Stat Med (1996) 1.39
Factors influencing enrollment in clinical trials for cancer treatment. South Med J (1999) 1.33
Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol (2005) 1.29
Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol (1996) 1.21
After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer. J Clin Oncol (1994) 1.21
Hazard function estimators: a simulation study. Stat Med (1999) 1.17
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol (2002) 1.15
Improved survival and reduction in local failure rates after preoperative radiotherapy: evidence for the generalizability of the results of Swedish Rectal Cancer Trial. Ann Surg (1999) 1.15
Patterns of care and survival for children with acute lymphoblastic leukaemia diagnosed between 1980 and 1994. Arch Dis Child (1999) 1.13
A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). Oncologist (2012) 1.12
Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol (1993) 1.12
Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole. Ann Oncol (1999) 1.06
Patterns of care and survival for adolescents and young adults with acute leukaemia--a population-based study. Br J Cancer (1999) 1.04
Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer: response and survival results. Br J Cancer (2002) 1.02
Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). J Clin Oncol (2007) 0.96
Selection bias in clinical trials of anaplastic glioma. Ann Neurol (1989) 0.94
Leukemia in Rochester (NY). A 17-year experience with an analysis of the role of cooperative group (ECOG) participation. Cancer (1985) 0.92
Protocol allocation and exclusion in two Danish randomised trials in ovarian cancer. Br J Cancer (1991) 0.90
Long-term survival in Hodgkin's disease patients. A comparison of relative survival in patients in trials and those recorded in population-based cancer registries. Eur J Cancer (2000) 0.89
Limited-stage small-cell lung cancer: patient survival after combined chemotherapy and radiation therapy with and without treatment protocols. Radiology (1995) 0.86
Cooperative groups and community hospitals. Measurement of impact in the community hospitals. Cancer (1983) 0.86
Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin's disease from 1969 to 1994. Eur J Cancer (1999) 0.84
Duration of survival of children with acute leukaemia. Report to the Medical Research Council from the Committee on Leukaemia and the Working Party on Leukaemia in Childhood. Br Med J (1971) 0.78
Incidence and outcomes of acute lung injury. N Engl J Med (2005) 21.56
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Influence of computer-aided detection on performance of screening mammography. N Engl J Med (2007) 8.58
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst (2009) 6.96
Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst (2002) 6.28
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol (2007) 6.11
Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst (2009) 5.62
Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med (2003) 5.60
A randomized trial comparing acupuncture, simulated acupuncture, and usual care for chronic low back pain. Arch Intern Med (2009) 4.96
Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care (2002) 4.88
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med (2008) 4.81
Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease. JAMA (2013) 4.67
Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA (2003) 4.54
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med (2015) 4.53
Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med (2013) 4.45
Performance benchmarks for screening mammography. Radiology (2006) 4.41
A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. J Natl Cancer Inst (2010) 4.04
Does utilization of screening mammography explain racial and ethnic differences in breast cancer? Ann Intern Med (2006) 3.95
Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol (2007) 3.92
Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med (2012) 3.86
Reason for late-stage breast cancer: absence of screening or detection, or breakdown in follow-up? J Natl Cancer Inst (2004) 3.86
Effectiveness of computer-aided detection in community mammography practice. J Natl Cancer Inst (2011) 3.62
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
Efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst (2005) 3.06
High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol (2009) 2.97
Association between mammography timing and measures of screening performance in the United States. Radiology (2005) 2.85
Increasing the power of identifying gene x gene interactions in genome-wide association studies. Genet Epidemiol (2008) 2.84
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol (2012) 2.72
Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol (2007) 2.69
A comparison between audio computer-assisted self-interviews and clinician interviews for obtaining the sexual history. Sex Transm Dis (2004) 2.62
Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol (2009) 2.61
Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer. J Clin Oncol (2012) 2.59
Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol (2005) 2.51
American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol (2011) 2.51
Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol (2011) 2.46
Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer (2006) 2.42
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med (2010) 2.40
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol (2006) 2.38
Concordance of breast imaging reporting and data system assessments and management recommendations in screening mammography. Radiology (2002) 2.36
Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer (2007) 2.31
Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol (2006) 2.26
What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev (2011) 2.25
Household smoking bans: which households have them and do they work? Prev Med (2003) 2.25
Trends in relative survival for ovarian cancer from 1975 to 2011. Obstet Gynecol (2015) 2.22
Studies of prostate-cancer mortality: caution advised. Lancet Oncol (2008) 2.22
Effect of acute lung injury and acute respiratory distress syndrome on outcome in critically ill trauma patients. Crit Care Med (2004) 2.20
Assessing antiretroviral adherence via electronic drug monitoring and self-report: an examination of key methodological issues. AIDS Behav (2007) 2.20
Models in the development of clinical practice guidelines. Ann Intern Med (2014) 2.18
Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Spec Pharm (2015) 2.15
Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness. J Natl Compr Canc Netw (2012) 2.13
Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol (2005) 2.11
Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 2.11
Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. J Clin Oncol (2008) 2.11
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics (2007) 2.09
Effect of breast augmentation on the accuracy of mammography and cancer characteristics. JAMA (2004) 2.07
Pre-pregnancy body mass index, gestational weight gain, and other maternal characteristics in relation to infant birth weight. Matern Child Health J (2007) 2.06
Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol (2013) 2.05
Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol (2003) 2.02
Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol (2011) 2.00
Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol (2012) 1.98
Effectiveness of screening examinations to detect unrecognized exercise-induced bronchoconstriction. J Pediatr (2002) 1.96
Measuring the performance of markers for guiding treatment decisions. Ann Intern Med (2011) 1.95
Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography. Cancer (2006) 1.92
Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr (2007) 1.91
Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. J Comp Eff Res (2012) 1.91
Does litigation influence medical practice? The influence of community radiologists' medical malpractice perceptions and experience on screening mammography. Radiology (2005) 1.87
Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med (2014) 1.87
Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines. Breast J (2006) 1.85
The impact of computerized provider order entry on medication errors in a multispecialty group practice. J Am Med Inform Assoc (2010) 1.85
Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol (2008) 1.83
Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med (2003) 1.79
Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. Arch Intern Med (2007) 1.77
Multi-modality mediastinal staging for lung cancer among medicare beneficiaries. J Thorac Oncol (2009) 1.76
Breast cancer yield for screening mammographic examinations with recommendation for short-interval follow-up. Radiology (2005) 1.75
p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst (2006) 1.74
Randomized phase II designs. Clin Cancer Res (2009) 1.73
Trends in hospital volume and patterns of referral for women with gynecologic cancers. Obstet Gynecol (2013) 1.72
Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology (2004) 1.71
Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol (2010) 1.71
Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. J Natl Cancer Inst (2012) 1.70
Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics. Med Decis Making (2013) 1.70
The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med (2007) 1.68
Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm (2015) 1.67
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol (2009) 1.67
It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. J Urol (2008) 1.66
Defining the limits of radical cytoreductive surgery for ovarian cancer. Gynecol Oncol (2011) 1.66
The causal effect of health insurance on utilization and outcomes in adults: a systematic review of US studies. Med Care (2008) 1.66
The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat (2009) 1.66
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat (2010) 1.65
The Breast Cancer Quality of Care Study (BQUAL): a multi-center study to determine causes for noncompliance with breast cancer adjuvant therapy. Breast J (2012) 1.64
Mammography facility characteristics associated with interpretive accuracy of screening mammography. J Natl Cancer Inst (2008) 1.61
Duffy (Fy), DARC, and neutropenia among women from the United States, Europe and the Caribbean. Br J Haematol (2008) 1.61
Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol (2008) 1.60
Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol Biomarkers Prev (2002) 1.60